GIP/GLP-1 receptor agonist
Tirzepatide dose
Answer
FDA label for Zepbound: The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Half-life on the label: approximately 5-6 days. Trials with posted results tested 5 doses, most often 15 mg, 10 mg, 5 mg.
Not dosing advice.
FDA LABEL
What the approved labels state
Zepbound NDA217806 · label of 2026-08-28 Regulator
The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks.
Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly.
Half-life: approximately 5-6 days (section 12.3).
Mounjaro NDA215866 · label of 2026-08-27 Regulator
The recommended starting dosage is 2.5 mg injected subcutaneously once weekly.
Maximum dosage: Adults: 15 mg subcutaneously once weekly.
Half-life: approximately 5 days (section 12.3).
IN TRIALS
Doses tested in 47 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 15 mg | 22 | 4,113 | 1/2/3/4 |
| 10 mg | 17 | 3,473 | 2/3 |
| 5 mg | 19 | 3,361 | 1/2/3/4 |
| 1 mg | 1 | 52 | 2 |
| 12 mg | 1 | 29 | 2 |
Trial register Read from the titles of arms that received Tirzepatide (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.